{
    "nctId": "NCT01156961",
    "briefTitle": "A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)",
    "officialTitle": "Post Registration Observational Program for Patients With Locally Recurrent or Metastatic Breast Cancer Who Receive Bevacizumab (Avastin) in Combination With Paclitaxel for the First-line Treatment",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Safety profile: Adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Locally recurrent or metastatic Her2-negative breast cancer\n* Locally recurrent disease must not be amenable to radiation therapy or resection with curative intent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Prior Adjuvant chemotherapy allowed; if taxane-based a disease-free interval after completion of \\>/=12 months is required\n* Adequate haematological, renal and liver function\n\nExclusion Criteria:\n\n* Previous chemotherapy for locally recurrent or metastatic disease\n* Radiation therapy for metastatic disease (except for relief of metastatic bone pain with irradiation of \\</= 30% of marrow-bearing bone)\n* CNS metastases\n* Pre-existing peripheral neuropathy\n* Clinically significant cardiovascular disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}